GlobeNewswire: Sarepta Therapeutics, Inc. Contains the last 10 of 290 releaseshttp://www.globenewswire.com/External?Length=42024-03-27T05:04:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/01/31/2599028/0/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-01-31T23:20:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2023/01/09/2585576/0/en/Sarepta-Therapeutics-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2022-Net-Product-Revenues.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues2023-01-09T18:28:00Z<![CDATA[- The Company expects to exceed 2022 full-year guidance for net product revenues]]>https://www.globenewswire.com/news-release/2023/01/03/2582181/0/en/Sarepta-Therapeutics-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference2023-01-03T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T.]]>https://www.globenewswire.com/news-release/2022/12/30/2581357/0/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2022-12-30T22:58:54Z<![CDATA[CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 13 individuals hired by Sarepta in December 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2022/11/30/2565491/0/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2022-11-30T23:00:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 42 individuals hired by Sarepta in November 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2022/11/28/2563009/0/en/Sarepta-Therapeutics-Announces-That-U-S-FDA-has-Accepted-for-Filing-and-Granted-Priority-Review-for-the-Biologics-License-Application-for-SRP-9001-Sarepta-s-Gene-Therapy-for-the-Tr.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy2022-11-28T12:00:00Z<![CDATA[– Regulatory action date of May 29, 2023]]>https://www.globenewswire.com/news-release/2022/11/23/2561611/0/en/Sarepta-Therapeutics-to-Present-at-the-Evercore-ISI-HealthCONx-Conference.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference2022-11-23T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022 at 2:15 p.m. E.T. The fireside chat will be held virtually.]]>https://www.globenewswire.com/news-release/2022/11/02/2547029/0/en/Sarepta-Therapeutics-Announces-Third-Quarter-2022-Financial-Results-and-Recent-Corporate-Developments.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments2022-11-02T20:05:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2022.]]>https://www.globenewswire.com/news-release/2022/10/31/2545050/0/en/Sarepta-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2022-10-31T22:00:31Z<![CDATA[CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 34 individuals hired by Sarepta in October 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2022/10/26/2541828/0/en/Sarepta-Therapeutics-to-Announce-Third-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=31865Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results2022-10-26T12:30:00Z<![CDATA[CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, November 2, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2022 financial results.]]>